In Vitro Activities of the Rx-01 Oxazolidinones against Hospital and Community Pathogens

Laura Lawrence, Paul N. Danese, J. A. DeVito, F. Franceschi, Joyce A. Sutcliffe

Antimicrobial Agents and Chemotherapy · 2008 · 71 citations · 48 references

DOIFull text

Open access

Concepts

Abstract

Rx-01_423 and Rx-01_667 are two members of the family of oxazolidinones that were designed using a combination of computational and medicinal chemistry and conventional biological techniques. The compounds have a two- to eightfold-improved potency over linezolid against serious gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant streptococci, and vancomycin-resistant enterococci. This enhanced potency extends to the coverage of linezolid-resistant gram-positive microbes, especially multidrug-resistant enterococci and pneumococci. Compounds from this series expand the spectrum compared with linezolid to include fastidious gram-negative organisms like Haemophilus influenzae and Moraxella catarrhalis. Like linezolid, the Rx-01 compounds are bacteriostatic against MRSA and enterococci but are generally bactericidal against S. pneumoniae and H. influenzae.

References

48